Related Funds
Fund Name | Location |
Aistar Ventures | Beijing, China, Haidian |
Avoro Ventures | - |
BBC | England, London, United Kingdom |
Changrong Ziben | China, Fujian, Xiamen |
Crawley Hatfield Capital | New York, New York, United States |
Exchange | - |
HH SPR-XV HK Holdings | China, Hong Kong, Hong Kong Island |
Inter Mutuelles Assistance | - |
Jinshi Investment | Beijing, Beijing, China |
Lambda Prime | Boston, Massachusetts, United States |
Malik Radix Healthcare | Delhi, Delhi, India |
On Grid Ventures | New York, New York, United States |
Pufeng Fund | Beijing, Beijing, China |
Real Web | Italy, Trentino-Alto Adige, Trento |
Smollan | Gauteng, NA - South Africa, South Africa |
Trident | - |
Union Square Hospitality Group | New York, New York, United States |
Walden Venture Capital | California, San Francisco, United States |
WE Hub | Andhra Pradesh, Hyderabad, India |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Junsai Shengwu | $23M | 15 Jan 2022 | - | ||
Haihe Biopharma | $185M | 24 Jul 2020 | Shanghai, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Junsai Shengwu | $23M | 15 Jan 2022 | - | ||
Haihe Biopharma | $185M | 24 Jul 2020 | Shanghai, China |